

STOCKED PRODUCTS REFERENCE

Blood factor products for patients with hemophilia

Scope. Preferred and alternative stocked blood factor products by coagulopathy and inhibitor status. Confirm current stock and dosing with Pharmacy, and involve Hematology for patients with inhibitors.

COAGULOPATHY	PREFERRED PRODUCT	ALTERNATIVE PRODUCT
HEMOPHILIA A — FACTOR VIII DEFICIENCY		
No inhibitors	Alphanate®	Humate-P®
With inhibitors UPDATED	FEIBA® Only if not receiving Hemlibra.	NovoSeven® Preferred if receiving Hemlibra.
HEMOPHILIA B — FACTOR IX DEFICIENCY		
No inhibitors	BeneFIX®	Profilnine®
With inhibitors UPDATED	NovoSeven®	FEIBA® Consult Anticoagulation Stewardship if considered.
VON WILLEBRAND DISEASE		
Inherent or acquired	Alphanate®	Humate-P®

PATIENTS RECEIVING HEMLIBRA

Emicizumab changes bypassing-agent selection in hemophilia A with inhibitors:
NovoSeven® is preferred and FEIBA® is reserved for patients not receiving Hemlibra.

BEFORE ORDERING

Confirm inhibitor status, current stock, and patient-specific dosing with Pharmacy.
Involve Hematology for any patient with inhibitors or an unclear factor diagnosis.

For clinician reference; individualize to the patient. This is a guidance document; it does not replace clinical judgment or a documented order.